Your browser doesn't support javascript.
loading
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study.
Navarria, Pierina; Pessina, Federico; Tomatis, Stefano; Soffietti, Riccardo; Grimaldi, Marco; Lopci, Egesta; Chiti, Arturo; Leonetti, Antonella; Casarotti, Alessandra; Rossi, Marco; Cozzi, Luca; Ascolese, Anna Maria; Simonelli, Matteo; Marcheselli, Simona; Santoro, Armando; Clerici, Elena; Bello, Lorenzo; Scorsetti, Marta.
Afiliação
  • Navarria P; Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Pessina F; Neurosurgical Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Tomatis S; Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Soffietti R; Consultant of Neurosurgical Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Grimaldi M; Neuroradiology Unit, Radiology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Lopci E; Nuclear Medicine Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Chiti A; Nuclear Medicine Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Leonetti A; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
  • Casarotti A; Laboratory of Motor Control, Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy.
  • Rossi M; Neurosurgical Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Cozzi L; Neurosurgical Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Ascolese AM; Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Simonelli M; Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Marcheselli S; Hematology and Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Santoro A; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
  • Clerici E; Department of Neurology, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Bello L; Hematology and Oncology Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy.
  • Scorsetti M; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Oncotarget ; 8(40): 67696-67708, 2017 Sep 15.
Article em En | MEDLINE | ID: mdl-28978064
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália País de publicação: Estados Unidos